Avenaciolide Induces Apoptosis in Human Malignant Meningioma Cells through the Production of Reactive Oxygen Species

Malignant meningioma has a poor prognosis and there are currently no effective therapies. Avenaciolide is water-insoluble natural organic product produced by Aspergillus avenaceus G. Smith that can inhibit mitochondrial function. In the present study, we investigated the anti-cancer effects of avena...

Full description

Saved in:
Bibliographic Details
Published in:Biological & pharmaceutical bulletin 2022/04/01, Vol.45(4), pp.517-521
Main Authors: Katsuzawa, Takumi, Kujirai, Kohei, Kamisuki, Shinji, Shinoda, Yo
Format: Article
Language:English
Subjects:
Antitumor activity
Apoptosis
avenaciolide
Brain cancer
Cancer
Cytotoxicity
Humans
Infant, Newborn
Lactones
malignant meningioma
Meningeal Neoplasms
Meningioma
Meningioma - drug therapy
Mitochondria
Neonates
Reactive oxygen species
reactive oxygen species (ROS)
Reactive Oxygen Species - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Malignant meningioma has a poor prognosis and there are currently no effective therapies. Avenaciolide is water-insoluble natural organic product produced by Aspergillus avenaceus G. Smith that can inhibit mitochondrial function. In the present study, we investigated the anti-cancer effects of avenaciolide in an isolated human malignant meningioma cell line, HKBMM. In addition, to assess the specificity of avenaciolide, its effects on normal human neonatal dermal fibroblast HDFn cells were also examined. Avenaciolide showed effective anti-cancer activity, and its cytotoxicity in HKBMM cells was greater than that in HDFn cells. The anti-cancer effects of avenaciolide were mediated by reactive oxygen species (ROS)-induced apoptosis, which may have been caused by mitochondrial disfunction. These results suggest that avenaciolide has potential as a therapeutic drug for malignant meningioma.
ISSN:0918-6158
1347-5215
DOI:10.1248/bpb.b21-01039